Thanks as always for truly excellent analysis. Wonder if you have a reaction to this observation:
Conveniently used lighter patients (~89kg) vs $vktx trials at ~100kg or >100kg for $lly zepbound trials. Lower starting weight means it is easier to show weight loss as a % of starting weight. Master play by $nvo
— underpaid analyst (@Kevin_M_Biotech) March 7, 2024
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.